Options in the treatment of chemotherapy-induced emesis

Cancer Practice

Volumn 6, Issue 5, 1998, Pages 276-281

  Pendergrass, Kelly B ^a,b  

^a Research Medical Center Brookside Campus   (United States)

^b Section of Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTINEOPLASTIC AGENT; AZASETRON; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DRONABINOL; DROPERIDOL; GRANISETRON; HALOPERIDOL; ITASETRON; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; NABILONE; ONDANSETRON; PREDNISONE; PROCHLORPERAZINE; PROMETHAZINE; SCOPOLAMINE; TETRAHYDROCANNABINOL; THIOPROPAZATE; TROPISETRON;

ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; HUMAN; PREVENTIVE MEDICINE; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING; VOMITING;

ACUTE DISEASE; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL PROTOCOLS; DRUG THERAPY, COMBINATION; HUMANS; INCIDENCE; NAUSEA; QUALITY OF LIFE; VOMITING;

EID: 0031709972     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5394.1998.00022.x     Document Type: Review

References (30)

1. Plosker GL, Benfield P. Granisetron: a pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting. PharmacoEconomics. 1996; 9: 357-374.
2. Lee M, Feldman M. Nausea and vomiting. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease: Pathophysiology/Diagnosis/Management. Philadelphia, Pa: W.B. Saunders; 1993;1:509-523.
3. Perez EA, Gandara DR. Advances in the control of chemotherapy-induced emesis. Ann Oncol. 1992;3(suppl 3):47-50.
4. Coates A, Abraham S, Kaye SB, et al. On the receiving end: patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19:203-208.
5. Sitzia J, Huggins L. Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for breast cancer. Cancer Practice. 1998;6:13-21.
6. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med. 1993;329:1790-1796.
7. Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol. 1989;7:1142-1149.
8. Laszlo J. Emesis as limiting toxicity in cancer chemotherapy. In: Laszlo J, ed. Antiemetics and Cancer Chemotherapy. Baltimore, Md: Williams & Wilkins; 1983:1-5.
9. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-109.
10. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol. 1995; 13:1036-1043.
11. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985;3: 1379-1384.
12. Andrykowski MA. The role of anxiety in the development of anticipatory nausea in cancer chemotherapy: a review and synthesis. Psychosom Med. 1990;52:458-475.
13. Mitchelson F. Pharmacological agents affecting emesis: a review (part I). Drugs. 1992;43:295-315.
14. Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev. 1953;5:193-230.
15. 1 receptor antagonist CP-99,994. Neuropharinacology. 1994;33:259-260.
16. 1 receptor. Br J Pharmacol. 1995;115:84-94.
17. 1 receptor antagonist GR203,040. Br J Pharmacol 1995;116: 3158-3163.
18. 1 receptor antagonist, in ferrets. Eur J Pharmacol. 1996;305:181-185.
19. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med. 1983;98:86-95.
20. Alphin RS, Proakis AG, Leonard CA, et al. Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility. Dig Dis Sci. 1986; 31:524-529.
21. DeMulder PHM, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, crossover study. Ann Intern Med. 1990;113:834-840.
22. Kendall BJ, McCallum RW. Gastroparesis and the current use of prokinetic drugs. Gastroenterologist. 1993;1:107-114.
23. Brogden RN, Carmine AA, Heel RC, et al. Domperidone: a review of its pharmacological activity, pharmacokinetics, and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs. 1982;24:360-400.
24. Hainsworth J, Harvey W, Pendergrass K, et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol. 1991;9:721-728.
25. Hesketh PJ, Beck T, Uhlenhopp M, et al. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. J Clin Oncol. 1995;13:2117-2122.
26. 3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Am J Clin Oncol. 1994;17: 137-146.
27. Pendergrass K, Audhuy B, Hesketh P, et al. Analysis of optimal dose from eight pooled clinical trials assessing the acute antiemetic efficacy of IV dolasetron mesylate (DM) after emetogenic chemotherapy (ECT). Proc Am Soc Clin Oncol. 1996; 15:547(abstr).
28. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992;10:1969-1975.
29. Perez EA. Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis. Clin Ther. 1996;18:578-590.
30. Kris MG, Pendergrass KB, Navari RM, et al. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol. 1997;15:2135-2138.